NHS Breast Screening Programme still effective in reducing deaths in England

November 22, 2020

An England-wide case-control study led by Queen Mary University of London has shown that, despite major improvements in diagnostic techniques and treatments, mammography screening continues to play an important role in lowering the risk of dying from breast cancer.

The study of over 23,000 women showed a 37% reduction in breast cancer mortality for women screened at least once, corresponding to approximately nine breast cancer deaths prevented between ages 55 and 79 for every 1000 women attending screening at ages 50-69. The effect of screening within the NHS Breast Screening Programme in England is stronger and longer lasting in women aged 65 or over, but it remains highly relevant for younger women.

Corresponding author Professor Stephen Duffy from Queen Mary University of London said: "The NHS Breast Screening Programme is doing its job in reducing the risk of death from breast cancer. Our results indicate that the benefit persists for 3-4 years in women aged under 65, so slippage of the three-year interval would be unsafe for these women.

"In the current Covid crisis, efforts to reinstate the breast screening programme should continue apace. If difficult decisions about delivery of the programme have to be made in the future, it may be appropriate to consider different intervals between screens for different age groups."
-end-
This research received funding from the Policy Research Programme of the Department of Health and Social Care and NIHR.

Research paper:
Roberta Maroni, Nathalie J Massat, Dharmishta Parmar, Amanda Dibden, Jack Cuzick, Peter D Sasieni, Stephen W Duffy. A case-control study to evaluate the impact of the breast screening programme on mortality in England. Br J Cancer 2020.

Queen Mary University of London

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.